close

SenoRx, Inc., a medical device company, develops, manufactures, and sells devices for the diagnosis and treatment of breast cancer. The company offers diagnostic products, including breast biopsy systems, and location and lymph node gamma ray detection devices; and marking products comprising tissue markers, which identify the biopsy site for future diagnostic and surgical reference. It also provides excising products, which is a tissue cutting devices designed to facilitate the contoured removal of lesions and facilitate the use of balloons in radiation therapy; and treatment products, including radiation balloons for localized partial breast radiation therapy. The company's breast biopsy systems include SenoRx Breast Biopsy Console, EnCor, EnCor 360(3), VisiLoc, SenoSonix, and SenoSonix Handcarry; tissue markers and location devices comprise Gel Mark, Gel Mark Ultra, Gel Mark UltraCor, SenoMark, Gel Mark UltraCor MRI, Tissue Marker Line Extension, Starch Mark, and Loc Wire Replacement; and gamma ray detection devices consist of Gamma Finder. Its excision and reconstruction products include SenoPulse RF Generator and Single Step; and radiation therapy products comprise Contura MLB, Contura Shape Select MLB, and CED Device. SenoRx, Inc. markets its products through direct sales force and distributors in the United States and internationally. The company was formerly known as BiopSolation Medical, Inc. and changed its name to SenoRx, Inc. SenoRx, Inc. was founded in 1998 and is headquartered in Irvine, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	11.00
Volume	0
Volume Avg	453345
52 Week High	11.03
52 Week Low	3.27
PE	N/A
PE (group average)	N/A
EPS Year	-0.17
EPS change Q/Q	-500%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-218.75%
REV change Q/Q	13.14%
REV change Q/Q Yr ago	13.97%
EPS next Q est	0.06
EPS next Y est	0.34
Divident Annual	0.00
Dividend Yield	0%